Free drug to market in EUA with 🤷♂️ data
⬇️
Offered to pts
⬇️
Sets expectation as std of care at unknown future price
⬇️
Free supply exhausted
⬇️
Hospitals/clinics must keep up std of care
⬇️
Will insurance companies pay for drug and if not who absorbs/pays for it?
Fascinating description of how population density should influence policies going forward -- no one size fits all! And cites the inoculum effect, which is probably much more important than we realize: More virus exposure, worse outcomes. @DrPaulOffit https://t.co/K66gLjnRR4
What makes some residents great&some average? Here’s the answer. I tell residents I’ll train u2b great if u want2b average I’m the wrong person. @TheBack140 @TheIDApprentice @antiviralpharmd @StewardshipJAX @real_idpharmd
Remdesivir, tocilizumab, sarilumab ... covering some recent clinical studies here, while trying to grab a drink of water from Niagara Falls with a glass (a.k.a., keeping up with #COVID19 research). h/t Canadian @HelenBranswell for the analogy. Latest: https://t.co/JCtIo01mgq
Dear PCPs: Please stop prescribing hydroxychloroquine for patients to have at home “just in case” they get COVID-19. This is depleting the supply for patients who actually get sick.
New in OFID: For patients with severe #sepsis, early consultation with an ID specialist was associated with 40 percent lower mortality: https://t.co/3ltRaCdnTw #OpenForumInfectDis#IDSAJournals@TMadalineID
Whenever I see a patient w/ a FQN 💊 allergy, I’m unsure whether to be excited that someone won’t choose them or sad that they have already been exposed🤷♂️. They’re a useful class of antibiotics, when used in the right situation.